-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Famitinib in Squamous Cell Carcinoma Drug Details: Famitinib (SHR-1020) is under...
-
Product Insights
Spinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirolimus in Lymphangioleiomyomatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Lymphangioleiomyomatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Lymphangioleiomyomatosis Drug Details: Sirolimus is under development for the treatment of...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LNK-01002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LNK-01002 Drug Details LNK-01002 is under development for the treatment of relapsed and refractory...
-
Product Insights
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tyrosine Protein Kinase JAK1 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in...